原发性高血压患者血清可溶性生长刺激表达 基因2蛋白与早期心脏重构的相关性研究
Study on the Correlation between Serum Soluble ST2 and Early Cardiac Remodeling in Patients with Essential Hypertension
摘要: 目的:探讨原发性高血压患者血清可溶性生长刺激表达基因2蛋白(sST2)与早期心脏重构的相关性。方法:选取2023年9月至2024年7月于心血管内科就诊的原发性高血压患者153例,根据超声心动图将病例分为两组:左心房正常组、左心房增大组;收集其临床资料并用ELISA法检测患者血清sST2水平,比较两组血清sST2水平,Spearman法分析血清sST2与心脏重构指标的相关性(左心房前后径、舒张末期室间隔厚度、左心室舒张末期内径、左心室收缩末期内径)。结果:左心房正常组106例,左心房增大组47例,左心房增大组较左心房正常组sST2水平显著升高(15.71 ± 8.80 ng/ml vs 12.47 ± 6.34 ng/ml, P = 0.026);sST2水平与左心房前后径(r = 0.199, P = 0.014)、室间隔厚度(r = 0.165, P = 0.042)呈正相关,sST2水平与左心室舒张末期内径、左心室收缩末期内径、左心室舒张末期容积、左心室收缩末期容积、射血分数无显著相关性(P > 0.05)。结论:原发性高血压患者血清sST2水平与左心房前后径及室间隔厚度存在微弱正相关,但未发现与其他左心室重构指标相关,提示sST2可能主要反映早期向心性重构而非左心室腔扩大。
Abstract: Objective: To investigate the association between serum soluble ST2 (sST2) levels and early cardiac remodeling in patients with essential hypertension. Methods: A total of 153 patients with essential hypertension admitted to the Department of Cardiology between September 2023 and July 2024 were enrolled. Based on echocardiographic findings, they were categorized into two groups: normal left atrium group and enlarged left atrium group. Clinical data were collected, and serum sST2 levels were measured using Enzyme-Linked Immunosorbent Assay (ELISA). The sST2 levels were compared between the two groups, and Spearman’s correlation analysis was employed to evaluate the relationship between sST2 levels and cardiac remodeling parameters, including left atrial anterior-posterior diameter, end-diastolic interventricular septal thickness, left ventricular end-diastolic diameter, and left ventricular end-systolic diameter. Results: A total of 153 patients with essential hypertension were included and categorized into two groups based on echocardiographic findings: the normal Left Atrium (LA) group (n = 106) and the enlarged LA group (n = 47). Serum soluble ST2 (sST2) level was significantly higher in the enlarged LA group than in the normal LA group (15.71 ± 8.80 ng/mL vs 12.47 ± 6.34 ng/mL, P = 0.026). Spearman correlation analysis revealed that sST2 level was positively correlated with left atrial anterior-posterior diameter (r = 0.199, P = 0.014) and interventricular septal thickness at end-diastole (r = 0.165, P = 0.042). In contrast, no significant correlations were observed between sST2 level and the following left ventricular parameters: end-diastolic diameter, end-systolic diameter, end-diastolic volume, end-systolic volume, or ejection fraction (all P > 0.05). Conclusion: Serum sST2 level is weakly positively correlated with left atrial diameter and interventricular septal thickness in patients with essential hypertension, but not with other left ventricular remodeling indices, suggesting that sST2 may primarily reflect early concentric remodeling rather than left ventricular cavity dilatation.
文章引用:包飞翔, 王萌, 王晓晨, 高峰, 方玉, 杨蕾. 原发性高血压患者血清可溶性生长刺激表达 基因2蛋白与早期心脏重构的相关性研究 [J]. 临床医学进展, 2026, 16(4): 1877-1883. https://doi.org/10.12677/acm.2026.1641428

参考文献

[1] Maeda, D., Dotare, T., Matsue, Y., Teramoto, K., Sunayama, T., Tromp, J., et al. (2023) Blood Pressure in Heart Failure Management and Prevention. Hypertension Research, 46, 817-833. [Google Scholar] [CrossRef] [PubMed]
[2] Garg, P., Assadi, H., Jones, R., Chan, W.B., Metherall, P., Thomas, R., et al. (2021) Left Ventricular Fibrosis and Hypertrophy Are Associated with Mortality in Heart Failure with Preserved Ejection Fraction. Scientific Reports, 11, Article No. 617. [Google Scholar] [CrossRef] [PubMed]
[3] Han, Y., Li, Y., Wu, Z., Pei, Y., Lu, S., Yu, H., et al. (2024) Progress in Diagnosis and Treatment of Hypertension Combined with Left Ventricular Hypertrophy. Annals of Medicine, 56, Article ID: 2405080. [Google Scholar] [CrossRef] [PubMed]
[4] 王嘉怡, 曲艺, 张增磊, 等. 高血压性心脏病的诊断及治疗研究进展[J]. 中国分子心脏病学杂志, 2025, 25(2): 6753-6764.
[5] Nemtsova, V., Burkard, T. and Vischer, A.S. (2023) Hypertensive Heart Disease: A Narrative Review Series—Part 2: Macrostructural and Functional Abnormalities. Journal of Clinical Medicine, 12, Article 5723. [Google Scholar] [CrossRef] [PubMed]
[6] Aimo, A., Januzzi, J.L., Vergaro, G., Richards, A.M., Lam, C.S.P., Latini, R., et al. (2020) Circulating Levels and Prognostic Value of Soluble ST2 in Heart Failure Are Less Influenced by Age than N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Troponin T. European Journal of Heart Failure, 22, 2078-2088. [Google Scholar] [CrossRef] [PubMed]
[7] Zhang, Y., Fan, Z., Liu, H., Ma, J. and Zhang, M. (2020) Correlation of Plasma Soluble Suppression of Tumorigenicity-2 Level with the Severity and Stability of Coronary Atherosclerosis. Coronary Artery Disease, 31, 628-635. [Google Scholar] [CrossRef] [PubMed]
[8] Paker, M., Pichkhadze, E., Miron, D., et al. (2023) Acute Otitis Media Bacteriology in Children Younger Than Three Months in the Last 16 Years. Harefuah, 162, 598-604.
[9] Wei, P., Liu, L., Wang, X., Zong, B., Liu, X., Zhang, M., et al. (2023) Expression of Soluble ST2 in Patients with Essential Hypertension and Its Relationship with Left Ventricular Hypertrophy. ESC Heart Failure, 10, 303-310. [Google Scholar] [CrossRef] [PubMed]
[10] 靳文英, 史歆然, 于超, 等. 依国人最新超声心动图数据判定左心房大小的方法学比较[J]. 中华超声影像学杂志, 2019, 28(1): 7-11.
[11] Kockskämper, J. and Pluteanu, F. (2022) Left Atrial Myocardium in Arterial Hypertension. Cells, 11, Article 3157. [Google Scholar] [CrossRef] [PubMed]
[12] 贾慧敏, 关丽娜. 室间隔基底段心肌肥厚作为高血压早期重构影像学标志物的研究进展[J]. 影像研究与医学应用, 2025, 9(7): 17-19.
[13] Huang, X., Hu, L., Long, Z., Wang, X., Wu, J. and Cai, J. (2024) Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment. Reviews in Cardiovascular Medicine, 25, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[14] Chen, J., Xiao, P., Song, D., Song, D., Chen, Z. and Li, H. (2022) Growth Stimulation Expressed Gene 2 (ST2): Clinical Research and Application in the Cardiovascular Related Diseases. Frontiers in Cardiovascular Medicine, 9, Article 1007450. [Google Scholar] [CrossRef] [PubMed]
[15] Arnaldos-Carrillo, M., Noguera-Velasco, J.A., Martínez-Ardil, I.M., Riquelme-Pérez, A., Cebreiros-López, I., Hernández-Vicente, Á., et al. (2023) Value of Increased Soluble Suppressor Tumorigenicity Biomarker 2 (sST2) on Admission as an Indicator of Severity in Patients with Covid-19. Medicina Clínica, 161, 185-191. [Google Scholar] [CrossRef] [PubMed]
[16] Chatterjee, A., Azevedo-Martins, J.M. and Stachler, M.D. (2023) Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights. OncoTargets and Therapy, 16, 675-687. [Google Scholar] [CrossRef] [PubMed]
[17] Farcaş, A.D., Mocan, M., Anton, F.P., Diana, M.L., Chiorescu, R.M., Stoia, M.A., et al. (2020) Short-Term Prognosis Value of sST2 for an Unfavorable Outcome in Hypertensive Patients. Disease Markers, 2020, Article ID: 8143737. [Google Scholar] [CrossRef] [PubMed]
[18] Gizatulina, T.P., Mamarina, A.V., Martyanova, L.U., Belonogov, D.V., Kolunin, G.V., Petelina, T.I., et al. (2024) The Soluble ST2 Level Predicts Risk of Atrial Fibrillation Recurrences in Long-Term Period after Radiofrequency Ablation. BMC Cardiovascular Disorders, 24, Article No. 460. [Google Scholar] [CrossRef] [PubMed]
[19] Sciatti, E., Merlo, A., Scangiuzzi, C., Limonta, R., Gori, M., D’Elia, E., et al. (2023) Prognostic Value of sST2 in Heart Failure. Journal of Clinical Medicine, 12, Article 3970. [Google Scholar] [CrossRef] [PubMed]
[20] Huang, Y., Lin, Y., Fu, M. and Zhang, W. (2025) Diagnostic Efficacy of Soluble ST2 in Pediatric Fulminant Myocarditis. Frontiers in Pediatrics, 13, Article 1417341. [Google Scholar] [CrossRef] [PubMed]
[21] Riccardi, M., Myhre, P.L., Zelniker, T.A., Metra, M., Januzzi, J.L. and Inciardi, R.M. (2023) Soluble ST2 in Heart Failure: A Clinical Role Beyond B-Type Natriuretic Peptide. Journal of Cardiovascular Development and Disease, 10, Article 468. [Google Scholar] [CrossRef] [PubMed]
[22] Zhu, Y., Pei, L., Li, N. and Zhu, Y. (2024) Preoperative sST2 Levels Relate to Myocardial Remodeling and Cardiac Function Improvement after Cardiac Valve Surgery. ESC Heart Failure, 11, 91-98. [Google Scholar] [CrossRef] [PubMed]